Drug intelligence / Profile preview

AEVI-005

Development stage: Preclinical
Lead developer: Avalo Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AEVI-005 is a monoclonal antibody in preclinical development for an undisclosed ultra-orphan pediatric autoimmune disease. It is the second monoclonal antibody developed under Aevi Genomic Medicine's collaboration with Kyowa Hakko Kirin. The specific mechanism of action and molecular target for AEVI-005 have not been publicly disclosed, and its precise indication within pediatric autoimmunity has also not been revealed[1][3][5][7][13][15][17].

Beyond the preview

Go deeper on AEVI-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEVI-005.

Explore the full profile